People vaccinated last year are twice as likely to contract COVID-19

Moderna Inc. has released a data set suggesting that its COVID-19 vaccine is effective in preventing serious health problems or death from “variants of concern,” but admitting that the effectiveness declines over time, so those who received the vaccine last year were twice as likely to contract a breakthrough case of coronavirus disease.

According to data, which Moderna released on Wednesday, a “study shows a lower risk of breakthrough infection in participants vaccinated more recently (median 8 months after first dose) than participants vaccinated last year (median 13 months). after the first dose) “.

COVID-19 KILLS AMERICANS AT 1 IN 500, DATA SHOWS

A Moderna trial conducted over the summer, titled Phase 3 COVE Study, found that “88 breakthrough cases of COVID-19 occurred in the most recently vaccinated group (49.0 cases per 1,000 person-years) against 162 cases in the group vaccinated last year. (77.1 cases per 1000 person-years). “

In both groups, Moderna stressed that “only 19 severe cases were observed”. While there was a “numerical trend towards a lower rate of severe cases in groups vaccinated more recently”. Moderna insisted the number of cases was low enough that the trend was “not significant”.

Research found that those who had been vaccinated earlier had a 50% higher rate of symptomatic rupture during the months of July and August compared to those who received the vaccination later.

In a statement released with the data, Moderna CEO Stéphane Bancel insisted the data “supports the need for a recall.”

“It is promising to see clinical and real evidence add to the growing body of data on the effectiveness of the Moderna COVID-19 vaccine,” Bancel said of the unpublished analysis. “The increased risk of major infections in COVE study participants who were vaccinated last year compared to more recently illustrates the impact of decreased immunity and supports the need for a booster to maintain high levels of protection.

Moderna has also sought clearance from the U.S. Food and Drug Administration for a third booster dose, which will be half the dose of its existing vaccine.